Background Alzheimer's disease is the commonest cause of dementia affecting older
people. One of the therapeutic strategies aimed at ameliorating the clinical manifestations of …

Cholinesterase inhibitors (ChE-Is) are the standard of therapy for treatment of patients with
Alzheimer disease (AD) and are the only class of drugs approved by the Food and Drug …

The purpose of this paper is to analyze the radical innovations to treat lung cancer, which
are generating a revolution in clinical practice, in order to provide fruitful health policy …

Lung cancer is the second most common type of cancer and it has the highest mortality rate
worldwide. The purpose of this paper is to analyse the evolutionary growth of knowledge of …

Alzheimer's disease is a devastating chronic disease that significantly increases healthcare
costs and affects the quality of life (QoL) of the afflicted patients and their caregivers …

Background: Rivastigmine tartrate is a reversible cholinesterase inhibitor indicated for the
symptomatic treatment of mild to moderate dementia. It was approved by the US Food and …

Objective: To investigate the costs to society of Alzheimer disease (AD) care in a
multinational, randomized, placebo-controlled trial of donepezil in patients with moderate to …

The aims of this study were to evaluate the duration of acetylcholinesterase inhibitors
(AChEI) utilization as well as the patients' cognition maintenance. This study was using …

Objective To consider the methods available to model Alzheimer's disease (AD) progression
over time to inform on the structure and development of model-based evaluations, and the …

The costs and consequences of donepezil versus placebo treatment in patients with mild to
moderate Alzheimer's disease (AD) were evaluated as part of a 1-year prospective, double …